Barchiesi Francesco, Giacometti Andrea, Cirioni Oscar, Arzeni Daniela, Silvestri Carmela, Kamysz Wojciech, Abbruzzetti Alessandra, Riva Alessandra, Kamysz Elzbieta, Scalise Giorgio
Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy.
Peptides. 2007 Aug;28(8):1509-13. doi: 10.1016/j.peptides.2007.07.010. Epub 2007 Jul 17.
The in vitro activity of the lipopeptide PAL-Lys-Lys-NH(2) (PAL), alone or combined with either fluconazole (FLU) or amphotericin B (AMB), was investigated against 14 Cryptococcus neoformans isolates. PAL MICs ranged from 1.0 to 4.0 microg/ml. Fungicidal activity was observed. Synergy, defined as a fractional inhibitory concentration (FIC) index of < or =0.5, was observed in 21.4% of PAL/AMB interactions. Antagonism (FIC index>4) was never observed. The broad antifungal activity and the positive interactions with AMB suggest that PAL can represent a promising candidate in infections due to C. neoformans.
研究了脂肽PAL-Lys-Lys-NH(2)(PAL)单独或与氟康唑(FLU)或两性霉素B(AMB)联合使用时对14株新型隐球菌分离株的体外活性。PAL的最低抑菌浓度(MIC)范围为1.0至4.0微克/毫升。观察到了杀菌活性。在21.4%的PAL/AMB相互作用中观察到协同作用,定义为分数抑菌浓度(FIC)指数≤0.5。从未观察到拮抗作用(FIC指数>4)。广泛的抗真菌活性以及与AMB的阳性相互作用表明,PAL可能是治疗新型隐球菌感染的一个有前景的候选药物。